Clinical Trial Search

Primary: Progression Free Survival (PFS) at the Time of Primary Results — 8.97; 11.30; 9.13; 13.63 Months — p=0.0010

Primary: Number of Participants With Tumor Response (Stable Disease) — 5 participants

Primary: Overall Response Rate (ORR) — 30 percentage of participants

Primary: 16 Weeks PFS Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) (Cohort 1) — 1; 7 Participants

Primary: Objective Response Rate Per Composite Response Criteria — 7.5; 48.6; 33.3 percent of participants

Primary: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer…

Primary: The Patient Clinical Profile (General Clinical Data and Breast Cancer Characteristics) — 63.5; 48.8; 84.1; 41.1 percentage of participants

Primary: Response Rate — 2; 13; 21; 1 Participants

Primary: Objective Response Assessed by the Independent Review Facility Using Response Evaluation Criteria in Solid Tumors (RECIST) — 25.7; 26.9 Percentage of patients

Primary: Objective Response for HER2+ Patients (Best Objective Response a Patient Has Ever Experienced on Study) — 3; 13; 10; 11 Participants

Primary: Number of Patients Who Completed All Planned Therapy — 45 participants

Primary: Percentage of Participants With an Objective Response as Assessed Through Independent Radiologic Review — 32.7; 32.7 percentage of participants

Primary: Overall Survival (PP Population) — 30.2; 26.1 months — p=0.1983

Primary: Percentage of Subjects Able to Complete > 85% of the Planned Dose on Schedule — 60 percentage of participants

Primary: Pathologic Complete Response (pCR) — 27 participants

Primary: Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen. — 14.3 months

Primary: Objective Response Rate (ORR) — 30.8; 31.0; 55.6 percentage of participants

Primary: Estimate Progression-free Survival — 16.9; 8.3 Months

Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0…

Primary: Hematological - Dose Limiting Toxicities — 1; 3; 7; 1 participants

Primary: Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors…

Primary: Cardiac Saftey — 68; 67; 66; 65 percentage of LVEF

Primary: Percentage of Participants With Pathologic Complete Response (pCR) — 38.9 percentage of participants

Primary: Part I: Progression Free Survival (PFS) by Biomarker — NA; NA; 13.963; 1.216 months

Primary: Complete Response (CR) Rate in the Brain at 12 Weeks Post-radiation Therapy (RT) Using the RECIST 1.1 Criteria Based on Brain Magnetic Resonance Imaging (MRI) — 5.8; 0…

Primary: Percentage of Participants With Adverse Events (AE), Serious Adverse Events (SAE), AEs With Grade >=3, and AEs Related To Treatment — 100; 100; 100; 100 percentage of…

Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months

Primary: Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) — 3; 3; 15; 15 Participants

Primary: Number of Patients With Complete Pathologic Response Rate, Observed Following Treatment With q3week Carboplatin, Weekly Abraxane and Weekly Trastuzumab in Resectable and…

Primary: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment — 0 participants